Skip to main content
. 2019 May 20;19:471. doi: 10.1186/s12885-019-5717-y

Fig. 3.

Fig. 3

Schema for registration and treatment of Platform Cohort 2. CHOP-R cyclophosphamide, doxorubicin, vincristine, prednisolone and rituximab; CR complete response; PR partial response; SD stable disease; PD progressive disease